CLINICAL_TRIALS
withdrawal
· 2012-10-10
Clinical Trial Update: Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia [Phase 2]
Summary
A Phase 2 trial of arsenic trioxide for refractory or relapsed chronic lymphocytic leukemia has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: WITHDRAWN